









Markets
/
Stocks
/
nasdaq-alec
/

Alector Inc

ALEC

1.960USD

+0.140+7.69%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

210.59MMarket Cap

LossP/E TTM



Alector Inc

1.960

+0.140+7.69%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alector Inc

Currency: USD Updated: 2026-02-06

Key Insights

Alector Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 145 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.10.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alector Inc's Score

Industry at a Glance

Industry Ranking

145 / 392

Overall Ranking

290 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Alector Inc Highlights

StrengthsRisks

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Fairly Valued

The company’s latest PE is -1.84, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 90.03M shares, increasing 10.00% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 41.28K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.92.

Analyst Rating

Based on 8 analysts

Hold

Current Rating

2.100

Target Price

+15.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Alector Inc is 5.60, ranking 346 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.26M, representing a year-over-year decrease of 78.75%, while its net profit experienced a year-over-year decrease of 17.89%.

Score

Industry at a Glance

Previous score

5.60

Change



Financials

5.18

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.33

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Alector Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Alector Inc is 7.04, ranking 183 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.84, which is -60.95% below the recent high of -0.72 and -229.95% above the recent low of -6.09.

Score

Industry at a Glance

Previous score

7.04

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 145/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Alector Inc is 5.75, ranking 350 out of 392 in the Biotechnology & Medical Research industry. The average price target is 1.50, with a high of 5.00 and a low of 0.75.

Score

Industry at a Glance

Previous score

5.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Hold

Current Rating

2.100

Target Price

+15.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Alector Inc

ALEC

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Alector Inc is 6.23, ranking 272 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.10 and the support level at 1.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.84

Change

0.39

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Neutral

RSI(14)

60.833

Neutral

STOCH(KDJ)(9,3,3)

55.210

Neutral

ATR(14)

0.115

High Vlolatility

CCI(14)

17.841

Neutral

Williams %R

29.508

Buy

TRIX(12,20)

0.808

Sell

StochRSI(14)

52.480

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.926

Buy

MA10

1.922

Buy

MA20

1.898

Buy

MA50

1.605

Buy

MA100

1.933

Buy

MA200

1.816

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Alector Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 98.61%, representing a quarter-over-quarter decrease of 7.38%. The largest institutional shareholder is The Vanguard, holding a total of 6.91M shares, representing 6.33% of shares outstanding, with 4.55% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

15.18M

+1.22%

TCG Crossover Management, LLC

10.00M

RTW Investments L.P.

6.99M

The Vanguard Group, Inc.

Star Investors

6.03M

+0.78%

Polaris Venture Partners

6.85M

-30.45%

Rosenthal (Arnon)

5.60M

-1.83%

BlackRock Institutional Trust Company, N.A.

5.52M

-10.74%

Merck & Co Inc

3.55M

Acadian Asset Management LLC

2.37M

+9.33%

T. Rowe Price Associates, Inc.

Star Investors

2.15M

-55.53%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alector Inc is 1.69, ranking 292 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alector Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.